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Exosome secretion is a notable feature of malignancy owing to the roles of these nanoparticles in cancer growth,
immune suppression, tumor angiogenesis and therapeutic resistance. Exosomes are 30–100 nm membrane vesicles
released by many cells types during normal physiological processes. Tumors aberrantly secrete large quantities of
exosomes that transport oncoproteins and immune suppressive molecules to support tumor growth and
metastasis. The role of exosomes in intercellular signaling is exemplified by human epidermal growth factor
receptor type 2 (HER2) over-expressing breast cancer, where exosomes with the HER2 oncoprotein stimulate tumor
growth and interfere with the activity of the therapeutic antibody HerceptinW. Since numerous observations from
experimental model systems point toward an important clinical impact of exosomes in cancer, several
pharmacological strategies have been proposed for targeting their malignant activities. We also propose a novel
device strategy involving extracorporeal hemofiltration of exosomes from the entire circulatory system using an
affinity plasmapheresis platform known as the Aethlon ADAPT™ (adaptive dialysis-like affinity platform technology)
system, which would overcome the risks of toxicity and drug interactions posed by pharmacological approaches.
This technology allows affinity agents, including exosome-binding lectins and antibodies, to be immobilized in the
outer-capillary space of plasma filtration membranes that integrate into existing kidney dialysis systems. Device
therapies that evolve from this platform allow rapid extracorporeal capture and selective retention of target
particles< 200 nm from the entire circulatory system. This strategy is supported by clinical experience in hepatitis C
virus-infected patients using an ADAPT™ device, the HemopurifierW, to reduce the systemic load of virions having
similar sizes and glycosylated surfaces as cancer exosomes. This review discusses the possible therapeutic
approaches for targeting immune suppressive exosomes in cancer patients, and the anticipated significance of
these strategies for reversing immune dysfunction and improving responses to standard of care treatments.
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A large body of literature has documented the relation-
ship between suppressed immune status and cancer pro-
gression resulting from tumor-mediated mechanisms as
well as from immune ablation caused by the therapeutic
agents themselves [1]. Although clinical trials have tested
a plethora of vaccination approaches against cancer,
tumor regression has been difficult to achieve and rever-
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reproduction in any medium, provided the orremains an important therapeutic goal. The possibility of
utilizing immune “de-repressive” approaches to augment
the efficacy of existing therapies is enticing; therefore,
there is a need to identify the appropriate targets and
develop avenues for interfering with their activity.
Numerous studies have shown that exosomes secreted
by tumor cells serve as vehicles for immune suppression
and other pro-cancer activities. Exosomes are one of a
heterogeneous group of microvesicles, distinguished by
their small size (30–100 nm) and cup shaped morph-
ology, that are secreted by a variety of cell types under
physiological and pathological conditions [2]. Exosome
biogenesis begins with endosomes that form in clathrin-
coated vesicles at the plasma membrane, which arel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cules that are present in endosomes can either be recycle
back to the plasma membrane or become incorporated
into intralumenal vesicles (ILV). These vesicles accumulate
in maturing endosomes by inward budding of the endoso-
mal membrane, thereby transforming endosomes into
multivesicular bodies (MVB). The sorting of cargo into ILV
is mediated by a protein complex known as the ESCRT
(endosomal sorting complexes required for transport) ma-
chinery that recognizes ubiquitinated proteins and facili-
tates their inclusion into ILV of MVB [4]. Subsequently,
MVB either fuse with lysosomes where their contents are
degraded or they fuse with the plasma membrane and
expel their internal vesicles, known as exosomes, into the
extracellular space through outward budding from the
membrane [5]. Tumor-derived exosomes are released lo-
cally and into the circulation to interact with a variety of
target cells, including other tumor cells, endothelial cells
and immune cells, which occurs via uptake of the exo-
somes by endocytosis, direct plasma membrane fusion, or
receptor-mediated adhesion to target cells [6]. The vacu-
olar H+-ATPase transmembrane pumps that maintain the
low pH of the tumor microenvironment are essential for
fusion of tumor-derived exosomes with target cells, which
is believed to be related to higher rigidity of exosomal
membranes at a lower pH [7]. Interestingly, one study
revealed that exosome secretion is induced by detachment
of breast cancer cells from substrata, and these exosomes
subsequently accumulate in lipid raft domains on the cell
surface for adhesion and spreading of tumor cells [8].
The ability of exosomes to serve as purveyors of long
distance signals between cells is facilitated by their
double-layer membrane enriched in cholesterol,
sphingomyelin, and ganglioside GM3 as well as by pro-
tective proteins against complement, thereby allowing
for a stable conformation and superior biodistribution of
their protein repertoire in comparison to free-floating
proteins [5]. All exosomes, irrespective of their cell type
of origin, contain a conserved set of proteins involved in
cell adhesion, cell structure, membrane fusion, metabol-
ism, and signal transduction [9]. Since exosomes also
contain cell-type specific proteins and genetic material
from their parental cells, the enrichment of tumor-
secreted exosomes for factors that promote malignancy
is being explored as a prognostic indicator of advancing
malignancy in several types of cancer [9]. In samples of
body fluids from cancer patients, including blood from
breast cancer [10], ovarian cancer [11], and glioblastoma
patients [12], and in urine samples from patients with
prostate cancer [13,14], cancer-specific proteins and
microRNA signatures in exosomes were found to serve
as biomarkers of tumor type and stage. Patients with
melanoma, lung cancer and gynecological cancers have
higher levels of circulating exosomes compared tohealthy subjects, and the concentrations of exosomes
correlate with the malignant behavior of the cancer [15–
18]. In a study of ovarian and endometrial cancer, micro-
vesicles from patients with advanced cancer were found
to contain matrix metalloproteinases and FasL, which
have roles in cancer cell invasion and killing of immune
cells, respectively, whereas these microvesicles were not
detected in sera from healthy control subjects or
patients with benign disease [17].
Exosomes as mediators of tolerance induction
Immunological functions of exosomes were first identified
in B cells through studies demonstrating that these cells
contain a late endocytic compartment, called MIIC [major
histocompatibility complex (MHC) class II-enriched com-
partment], that harbors newly synthesized MHC class II
molecules in transit to the plasma membrane [19]. It was
demonstrated that the MIIC compartment fuses with the
plasma membrane, leading to the release of vesicles that
display MHC class II molecules and are capable of stimu-
lating antigen-specific T cell responses in vitro as well as
in vivo [20]. These vesicles were termed “exosomes” in
reference to the original work on reticulocytes [21]. A
plethora of immune stimulatory roles for exosomes have
been uncovered, including exosome-mediated promotion
of T cell-mediated autoimmunity [22] and induction of
immune responses directed against intracellular pathogens
[23–25]. Moreover, exosomes derived from tumor
antigen-loaded dendritic cells (DC) could be exploited as
cell-free cancer vaccines, owing to their display of MHC/
peptide complexes and their capacity to stimulate NK
cell- and T cell responses in experimental animals and
cancer patients [26–29].
The discovery that exosomal cargo mirrors that of
their originating cell types has lead to the understanding
that exosomes can be either immune stimulatory or tol-
erogenic depending on the originating cell’s activation
state and the cellular cargo that is packaged into the
vesicles. DC are key orchestrators in whether immune
activation or immune tolerance occurs as a result of
their interactions with T cells. It has been reported that
immature DC promote induction of tolerance [30], and
that administration of these “tolerogenic DC” can sup-
press autoimmunity in vivo [31]. Given observations that
exosomes derived from mature DC are immune stimula-
tory [32,33], the theory was tested that exosomes
secreted by tolerogenic dendritic cells could serve as
vehicles for suppressing inflammatory responses. Indeed,
Ruffner et al. showed that dendritic cells treated with IL-
10 to block their maturation secrete exosomes that in-
hibit delayed-type hypersensitivity reactions in an
antigen-specific manner, an effect requiring CD80 and
CD86 co-stimulatory molecules on exosomes, possibly
for direct interactions with T cells [34]. Similarly, Yang
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ture DC to enhance intestinal allograft survival in a rat
transplantation model [35]. This group demonstrated
that as little as 20 μg of donor- (but not recipient-)
derived exosomes were capable of significantly prolong-
ing graft survival. Prolongation of graft survival with
exosomes from immature DC was also observed in a
cardiac allograft model [36]. Kim et al. demonstrated
that the exosomes produced by tolerogenic DC were on
average 75 nm in size and mediated their suppressive
effects on T cells through their display of Fas ligand [37].
Although exosome production by tolerogenic DC propa-
gated in vitro could be considered artefactual, there are
also many naturally occurring examples of exosomes as
mediators of immune tolerance.
Pregnancy represents an in vivo example where exo-
somes promote immune tolerance to the “fetal allograft”.
During pregnancy, local and systemic immune deviation
occurs [38] and the failure to induce this “natural immune
modulation” is associated with recurrent spontaneous
abortions [39,40]. Interestingly, exosome production has a
role in directing the maternal immune system to accom-
modate the allogeneic fetus. Frängsmyr et al. reported that
freshly isolated fetal syncytiotrophoblast cells store Fas lig-
and (fasL) in cytoplasmic granules that are released as
exosomes, likely for the purpose of inducing apoptosis of
fetus-sensitized effector T cells expressing fas [41]. As dis-
cussed in the context of dendritic cell-derived exosomes,
FasL on these microvesicles is associated maintaining a
state of immune privilege or tolerance. It is also plausible
that exosomes bearing antigen/MHC complexes transmit
death signals that cause specific killing of the T cell clones
that pose a threat to the exosome-producing cell. This
functional association was explored by Dr. Douglas Tay-
lor’s group who observed that pre-term deliveries are
associated with higher degrees of maternal anti-fetal im-
munity, as measured by TCR-zeta chain activity, and
lower concentrations of FasL+ exosomes [42].
Pregnancy-associated exosomes possess multiple
means for modulating T cell responses. For example, the
inhibitory molecule PD-1 ligand is found on pregnancy-
derived exosomes in circulation, and can inhibit both
CD4+ and CD8+ T cells [43]. Exosomes released by the
syncytiotrophoblast of the human placenta are potently
inhibitory toward maternal NK cells, CD8+ T cells, and
gamma delta T cells through their expression of MHC
class I chain-related proteins A and B (MICA/B), and
UL-16 binding proteins (UL-BP), which are a family of
ligands that bind to the natural killer activating receptor
NKG2D [44,45]. Interestingly, pregnant women exhibit
substantially lower expression of NKG2D on their lym-
phocytes as compared to non-pregnant women [45].
Culture of peripheral blood mononuclear cells from
non-pregnant women with exosomes from pregnantwomen resulted in downregulation of NKG2D expres-
sion and suppressed NK cell activity. The immune toler-
ance that occurs during pregnancy has been associated
with remission of autoimmunity in clinical cases of
rheumatoid arthritis [46] and multiple sclerosis [47], a
phenomenon that has been suggested to involve
pregnancy-associated exosomes that suppress T cell
responses systemically [48].
Another physiological example of exosome-mediated
immune tolerance is the antigen-specific immune modu-
lation that can be elicited in response to oral antigen ad-
ministration. Induction of oral tolerance is associated
with the generation of T regulatory (Treg)/Th3 cells
with specificity for food-borne antigens [49]. Clinical
trials of oral tolerance in rheumatoid arthritis [50], and
multiple sclerosis [51,52], have shown some promising
results, although the efficacy of these treatments has not
met the bar for clinical approval. It was demonstrated
that subsequent to feeding with a nominal antigen,
plasma-circulating exosomes containing MHC II and the
specific antigen could be isolated [53]. These exosomes,
termed “tolerosomes”, originate from intestinal epithelial
cells and engage in MHC-restricted interactions with
CD4+ T cells that suppress immunological effector
responses in response to the fed antigen [54]. In a mur-
ine allergy model, protection from allergy could be
transferred via exosomes collected from mice that had
been fed the allergen orally [55]. These data suggest that
tolerance induction may occur through the generation
of exosomes, as also observed for pregnancy- and
cancer-associated exosomes.
Tolerogenic functions of cancer exosomes
contribute to immune evasion
Many of the tolerogenic effects of exosomes secreted by
healthy cells are also imparted by tumor-derived exo-
somes, as represented in Figure 1 and described below.
The interactions between tumor-derived exosomes and
immune cells are mediated through direct signaling inter-
actions via surface-expressed molecules or by transfer of
exosomes and/or their cargo to immune cells (Figure. 1).
Exosomes also transport mRNAs and microRNAs to tar-
get cells, allowing for the direct exchange of genetic ma-
terial originating from tumor cells [56]. Many of the
signals delivered to immune cells via cancer exosomes are
involved in directing the immune system to specifically ig-
nore cancer cells. At the level of T cell immunity, exo-
somes possess enzymatic activity that causes hydrolysis of
ATP into adenosine in the tumor microenvironment,
which negatively regulates T cell activation [57]. Surface
display of FasL and TRAIL on microvesicles directly
engages the corresponding receptors on CD8+ T cells to
induce apoptosis [58–62]. Clinical consequences of FasL
on exosomes are suggested by observations that the ability
Figure 1 Mechanisms of immune tolerance mediated by tumor-derived exosomes. Exosomes evoke numerous immune suppressive
pathways during their interactions with immune cells. Depicted are examples of immune suppressive interactions between tumor-derived
exosomes and immune cells and their downstream effects on specific immune functions. Examples of direct adhesion and signaling interactions
between surface-expressed proteins on immune cells are depicted, whereby exosomes elicit apoptosis signaling, induction of immune
suppressive activity, and blockade of receptors/ligands required for anti-cancer immunity. Alternatively, exosomes and/or their contents, including
proteins (PRO) and genetic material (mRNA and microRNA), are delivered directly into target cells via exosomal fusion with the target cell
membrane or endocytosis. Cells that reportedly take up exosomes include immune cells (example shown) and tumor cells, which are endowed
with the ability to evade immune responses through the horizontal transfer of exosomal cargo.
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cles to induce T cell apoptosis in vitro correlates with dis-
ease activity and lymph node metastasis in head and neck
cancer patients [63]. FasL on the surfaces of tumor-
derived exosomes mediates cleavage of the TCR-zeta
chain, a crucial T cell signaling molecule that is required
for activation [64,65]. Low expression levels of TCR-zeta
chain correlate with impaired immune responses and are
predictive of poor prognosis of patients with several types
of cancer [66–71].
Tumor-derived exosomes also promote antigen non-
specific immune suppression through their effects on
myeloid-derived suppressor cells (MDSC), a population of
immature myeloid cells that are among the major inhibi-
tors of T cell activation in cancer [72]. Accordingly,
increased frequencies of MDSC are often detectable in the
circulation of cancer patients [73,74]. Tumor-derived exo-
somes direct the differentiation of bone marrow myeloid
progenitors to MDSC through their expression of an array
of bioactive molecules, including PGE2 and TGF-β [75].
Interestingly, there is also a correlation between cancer
progression and increased packaging of PGE2 and TGF-β
into exosomes, which could contribute to the increasedimmune suppressive properties of growing tumors [75].
Cancer exosomes expressing Hsp72 also stimulate toll-like
receptor 2 (TLR2) on MDSC, causing increased MDSC-
mediated immune suppressive activity against T cells
in vitro [76]. Collectively, these lines of evidence suggest
that cancer exosomes increase the numbers and activity of
immune suppressive cell populations.
The effects of cancer exosomes on the myeloid lineage
also extend to maintaining immaturity of DC, which is
associated with cancer progression in tumor-bearing
hosts [77]. A study of ovarian cancer exosomes har-
vested from ascites fluid demonstrated their ability to in-
duce apoptosis of DC through a Fas ligand-dependent
mechanism [61]. Exosomes from human breast cancer
cells inhibit the differentiation of monocytes into DC
in vitro [78]. Similarly, microvesicles from the plasma of
advanced melanoma patients, but not from healthy
donors, promote the differentiation of monocytes with
TGF-β-secreting activity that suppressed T cell activa-
tion and cytolytic activity [79]. Aberrantly elevated levels
of TGF-β in cancer serve to increase the activity of Treg
cells that promote immune suppression [80]. Addition-
ally, tumor-derived exosomes also display TGF-β on
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suppressive effects of Treg cells in vitro [81]. Whiteside’s
group reported that tumor-derived microvesicles induce
the expansion of CD4+ CD25+ FoxP3+ cells while indu-
cing apoptosis of tumor-reactive CD8+ T cells [82,83].
NK cells play a critical role in tumor immune surveil-
lance, as exemplified by a study that showed a higher inci-
dence of spontaneous tumors in mice deficient in NKG2D
[84], an activating immune receptor that is expressed by
cytotoxic cells, including NK cells and CD8+ T cells [85].
Ligands for NKG2D are generally only expressed during
cellular stress such as the DNA damage response that is
initiated in response to oncogene expression [86,87]. In
addition to expressing NKGD ligands, tumors also shed
soluble ligands that cause downregulation of the corre-
sponding receptor on immune cells, thereby impairing
their recognition of neoplastic cells [88]. Tumor-derived
exosomes display NKG2D ligands, including MICA/B,
ULBP1 and ULBP2, which mask NKG2D and mediate
downregulation of this receptor on NK cells and CD8+ T
cells [89–92]. TGF-β1 expression by exosomes [90] also
contributes to NKG2D downregulation and impaired NK
cell function in cancer patients [93]. Notably, the exoso-
mal form of NKG2D is more effective at suppressing im-
mune cells than the soluble form since the former allows
for proper orientation and biodistribution of NKG2D
ligands in a stable conformational arrangement [94].
Cancer exosomes spread tumor growth signals
that counteract the activity of therapeutic agents
Exosomes have emerged as major players in transporting
soluble proteins involved in cancer growth, including
members of the human epidermal receptor (HER) fam-
ily, which are constitutively active in many cancers as a
result of gene amplification, protein over-expression,
and/or mutations of their tyrosine kinase domains [95].
The HER family of tyrosine kinase receptors includes
four members: HER1/epidermal growth factor receptor
(EGFR), HER2, HER3 and HER4 that are expressed on
tumor cell surfaces to mediate cellular growth and sur-
vival signals [96] during interactions with their ligands
in the tumor microenvironment [97,98]. Exosomes
secreted by HER-over-expressing cancers, including
breast [99–101], pancreatic [102], brain [103,104], and
gastric cancer [105], have been shown to display HER
proteins from their native tumors. For example, in HER2
over-expressing breast cancer, an aggressive form of dis-
ease that accounts for 25 % of all breast cancers [106],
exosomes display the HER2 oncoprotein on their sur-
faces [99–101]. Cancers that exhibit HER-dependent
growth have also been reported to release exosomes that
display EGFR ligands, including amphiregulin [107],
TGF-α [107], heparin-binding EGF-like growth factor(HB-EGF)[107], EGFR [108] and the truncated and con-
stitutively active form of EGFR, variant III (EGFRvIII),
which causes unregulated growth of cancer cells [104].
Display of HER family members and their ligands on
exosomes facilitates the spread of growth-stimulating
and metastatic signals to several types of target cells. In
a study by Al-Nedawi et al. [104], microvesicles derived
from glioma cells transferred EGFRvIII to receptor-null
glioma cells to promote mitogenesis, pro-survival signal-
ing, and expression of VEGF [104]. EGFR from tumor-
derived microvesicles can also be transferred to endothe-
lial cells, eliciting VEGF upregulation and tumor angio-
genesis [108]. In another study, exosomes from breast
cancer and colorectal tumors displayed amphiregulin on
their surfaces, which engaged with HER1/EGFR on
tumor cells to increase their invasiveness [107]. Signifi-
cantly, exosomal amphiregulin was found to be 5 times
more efficient at increasing tumor invasiveness com-
pared to the same concentration of soluble recombinant
amphiregulin [107]. These data point toward tumor-
derived exosomes as being major purveyors of oncogenic
signals between cells.
An important pro-cancer effect of cancer exosomes is
in mediating resistance to immunotherapeutic agents.
The humanized monoclonal antibody HerceptinW (tras-
tuzumab; Genentech Inc., San Francisco, CA), which
binds to the extracellular domain of HER2, is the stand-
ard of care for breast cancers with HER2 amplification.
HerceptinW binds to HER2 with high affinity and evokes
a broad range of anti-tumor effects including direct in-
hibition of HER signaling, induction of antibody-
dependent cell cytotoxicity (ADCC) by NK cells and pos-
sibly through downregulation (internalization) of HER
proteins [109]. HER2 displayed on the surfaces of breast
cancer exosomes has been shown to bind and sequester
the therapeutic monoclonal antibody HerceptinW, thereby
allowing continued tumor cell proliferation [101]. This
decoy effect of breast cancer exosomes also shields target
cells from ADCC mediated by NK cells [100]. The obser-
vation that advancing cancer is associated with increased
exosome secretion by tumors as well as increased exo-
some binding to HerceptinW suggests that exosomes per-
mit cancer progression and metastasis by limiting drug
availability [101]. Indeed, exosome secretion in HER2
over-expressing breast cancer could be a contributing fac-
tor to the fact that the overwhelming majority of breast
tumors become refractory to treatments directed at HER2
[110–113]. The schematic in Figure 2 depicts the roles of
cancer exosomes in resistance to monoclonal antibody
therapy, illustrating exosomes in HER2 over-expressing
cancer as an example.
A second example of exosome-mediated resistance to
monoclonal antibody therapy is observed in B cell
lymphoma. CD20-bearing tumor exosomes have been
AB
C
Figure 2 Proposed effects of exosome depletion on the activity of therapeutic antibodies in cancer. (A) Tumor-secreted exosomes display
oncoproteins from their originating tumor cell. This example depicts HER2 over-expressing tumor cells releasing HER2+ exosomes that promote
tumor growth and immune suppression, as described in [99–101]. (B) Monoclonal antibodies administered for immunotherapy can be
sequestered by tumor-derived exosomes, owing to the display of oncogenic proteins on the exosomal surfaces [99–101,114]. In this example,
HER2+ exosomes bind to anti-HER2 antibodies (for example, HerceptinW) and limit the bioavailability of antibodies. Consequently, continued
tumor growth is permitted via interactions between HER proteins on the surfaces of tumor cells (consisting of dimers of HER2 with another HER
family member), and growth factors/EGFR ligands in the tumor microenvironment. (C) A strategy for therapeutic filtration of exosomes from the
circulation (shown here) or pharmacological methods of targeting exosome release by cancer cells could enhance the efficacy of
immunotherapy. Conceptually, removal of exosomes from the bloodstream would allow therapeutic anti-HER2 antibodies to block HER-related
signaling on tumor cells, thereby also alleviating exosome-mediated immune suppression and other pro-cancer activities.
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bodies (i.e. the therapeutic antibody rituximab) and also
consume complement, thereby impairing ADCC and
complement-dependent cytolysis against tumors [114].
Strikingly, in patients undergoing treatment for B cell
lymphoma, approximately one third to one half of the
plasma rituximab is bound to exosomes three hours fol-
lowing administration of the therapeutic antibody [114].
Removal of exosomes from plasma samples resulted in
significant improvements in the cytolytic activity of rituxi-
mab against tumor cell lines and against autologous tumorcells in vitro. These data suggest that a strategy for target-
ing exosomes could be beneficial for unmasking the effi-
cacy of therapeutic antibodies.
In addition to interfering with the activity of immu-
notherapeutic agents, tumor-derived exosomes also par-
ticipate in the resistance of tumors to certain
chemotherapy drugs. A role of exosomes in drug export
from tumor cells was suggested by observations that
cisplatin-resistant ovarian cancer cells displayed reduced
lysosomal content of platinum and increased secretion of
exosomes containing platinum as compared to cisplatin-
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oma cells occurs via secretion of intracellular organelles
called melanosomes, thereby impairing the drug’s
localization to the nucleus [116]. In a study by Shedden
et al. [117], the chemosensitivity profiles of NCI’s panel of
60 cancer cell lines were inversely correlated with expres-
sion of genes related to vesicle secretion. Accordingly,
intra-vesicular accumulation of the therapeutic agent
doxorubicin was associated with high rates of vesicle
shedding by chemoresistant cells [117]. Based on these
observations, the idea has been raised that drugs that
interfere with microtubule stability, such as taxanes and
vinca alkaloids, could serve as inhibitors of exosome se-
cretion [118]. Although these drugs are already used for
treating specific cancers, the cytotoxicity of these agents
would hinder their applicability as additive therapies for
ameliorating tumor-derived exosomes in cancer patients.
Accordingly, other means for modulating exosomes are
being explored, such as methods for altering the compos-
ition of exosomal proteins that promote malignancy [118].
For example, the dietary polyphenol curcumin reduces the
immune suppressive activities of breast cancer exosomes
against NK cells, which is believed to occur due to altera-
tions in ubiquitination of proteins during sorting of cargo
into ILV [119].
A promising alternative for inhibiting exosome secre-
tion involves targeting vacuolar H+-ATPase-driven efflux
pumps using proton pump inhibitors (PPIs), which are
widely prescribed for suppressing gastric acid [120]. Since
the activity of PPIs depends on acidic conditions, these
agents should exhibit a degree of selectivity for tumors
without introducing toxicity [1]. Vacuolar H+-ATPases are
overactive in tumors, pumping high concentrations of
protons across the plasma membrane to generate highly
acidic extracellular microenvironments [120,122]. PPIs
disrupt these pH gradients, leading to intracellular acidifi-
cation and death of cancer cells [121]. Significantly, PPIs
have been demonstrated to impair the release of acidic
vesicles by cancer cells, thereby increasing the cytoplasmic
retention of cytotoxic drugs and sensitizing tumors to che-
motherapeutic agents [120]. In one study of three mouse
tumor models, inhibition of exosome secretion using di-
methyl amiloride, an inhibitor of H+/Na+ and Na+/Ca2+
channels, was effective for mitigating the immune sup-
pressive effects of exosomes and restoring the responsive-
ness of cancer-bearing hosts to the chemotherapeutic
agent cyclophosphamide [76]. The DMA analog amiloride,
which also inhibits exosome release, was shown to decrease
the immune suppressive activity of serum from 11 patients
with colorectal cancer who were receiving this agent for
hypertension [76]. Another possible option for targeting
exosome secretion involves using sphingomyelinase inhibi-
tors. Indeed, exosomes are enriched for ceramide, which is
generated through the activity of sphingomyelinases and isinvolved in sorting of endosomal proteins into MVB [123].
Hence, the diverse pharmacological approaches for inhibit-
ing exosome secretion should be investigated further and
compared for their in vivo efficacy at unmasking immune
function and therapeutic responses in cancer.
Extracorporeal Hemofiltration of Circulating
Factors as a Therapeutic Strategy in Cancer
Another promising cancer treatment strategy involves
extracorporeal hemofiltration of immune suppressive
factors including exosomes from the circulation. In a
pioneering study by Dr. Rigdon Lentz, continuous whole
blood ultrapheresis was used to remove low molecular
weight proteins (<120, 000 daltons molecular weight)
from the blood of 16 cancer patients of which 6 patients
presented with a minimal 50 % reduction in the sizes of
their tumors [124]. The primary targets were considered
to be serum cytokine receptors that impede anti-
neoplastic immune responses [125] since exosomes and
their roles in cancer were not appreciated at that time.
Clinical approval was also granted for application of the
Prosorba Column, known as “Protein-A Immunoadsorp-
tion Therapy”. This plasma filtering device consists of
highly purified protein A from Staphylococcus aureus
covalently linked to a silica matrix to capture circulating
immunoglobulin G (IgG) and immune complexes con-
taining IgG, which was FDA-approved for rheumatoid
arthritis and idiopathic thrombocytopenic purpura as a
complementary therapy for clearing pathogenic auto-
antibodies. In a study examining the efficacy of the Pro-
sorba column in cancer, there was a measurable
reduction in tumor burden in 22 of 104 patients and
increased immune system activity reportedly occurred in
the hours following treatment [126,127]. However, in a
Phase II trial of metastatic breast cancer, circulating im-
mune complexes were not detected in the majority of
patients and treatment with the Prosorba column did
not confer clinical benefits [128].
Given the recent appreciation for the roles of exosomes
as malignancy-associated factors, an extracorporeal strategy
for specifically targeting exosomes is an attractive thera-
peutic option for cancer. Aethlon Medical has devised a
therapeutic hemofiltration approach, termed the Aethlon
ADAPT™(adaptive dialysis-like affinity platform technology)
system. This technology consists of immobilized affinity
agents in the outer-capillary space of hollow-fiber plasma
separator cartridges that integrate into standard dialysis
units or continuous renal replacement therapy (CRRT)
machines. As the patient’s blood passes through device,
plasma components< 200 nm in size travel through the
porous fibers and interact with the immobilized affinity
agent(s) to which target molecules are selectively adsorbed
while blood cells and non-bound serum components pass









Figure 3 Schematic of Aethlon’s ADAPT™ device platform. This
technology consists of plasmapheresis cartridges that allows blood
cells to pass through the hollow fibers while serum
components< 200 nm in size fit through the hollow fiber pores to
interact with the affinity matrix. The matrices can be customized
with one or more affinity substrates comprising monoclonal
antibodies, lectins, aptamers or other affinity agents to specifically
capture and remove tumor-derived exosomes and other soluble
oncoproteins from the bloodstream using kidney dialysis or CRRT
units.
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other affinity reagents, such as aptamers and protein
ligands, can be incorporated into the cartridges for captur-
ing single or multiple targets. Although ADAPT™ therapies
require that patients undergo a surgical procedure for vas-
cular access, this subtractive strategy for addressing cancer
exosomes would not introduce drug toxicity or interactions
risks, thereby offering an advantage over pharmacological
approaches. Hence, this device strategy offers an approach
for targeting exosomes that should be examined for its util-
ity as an adjunct therapeutic candidate to standard of care
cancer treatments.
There is a clinical precedent that supports the safety
and efficacy of affinity hemodialysis using ADAPT™
devices. The first ADAPT™ device, the HemopurifierW,
consists of a plasmapheresis cartridge to which the lectin
Galanthus nivalis agglutinin (GNA) is covalently coupled
to capture viruses on the basis of the high mannose glyco-
proteins on viral envelopes [129]. Aethlon has conducted
clinical studies of patients infected with hepatitis C virus
(HCV) that were treated with the HemopurifierW inserted
into standard dialysis extracorporeal circuits for up to 3
times weekly for 4–6 hours/treatment. Of the approxi-
mately 100 treatment experiences with the HemopurifierW
thus far, this therapy was well tolerated and the frequen-
cies of device-related adverse events were within the range
of those occurring during routine dialysis (data not
shown). HemopurifierW therapy reduced the viral load in
HCV-infected patients who were not concurrently receiv-
ing anti-viral drugs, and had a remarkable impact in im-
proving patient responses to ribarvirin and pegylated
interferon therapy ([129] and data not shown).Tumor-derived exosomes are enriched for high man-
nose structures on their surface glycoproteins [130] and
have been demonstrated to bind to lectins, including
GNA ([131] and our unpublished observations). Given the
similarity in size and surface topology between virions and
cancer exosomes [132], the HemopurifierW is currently
being evaluated for its efficacy for capturing exosomes
secreted by tumor cell lines and present in biologic fluids
from cancer patients. Since ADAPT™ devices implement-
ing antibodies as affinity substrates have been constructed
for other indications [133,134], an antibody-based ap-
proach could similarly be utilized for recognizing tumor-
specific proteins on exosomal surfaces in order to capture
cancer exosomes while sparing exosomes produced by
non-malignant cells. For example, in HER2 over-
expressing breast cancer, anti-HER2 antibodies could be
utilized to remove HER2 expressing exosomes as well as
soluble HER2, which is proteolytically cleaved from the
cancer cell surface and also neutralizes the activity of Her-
ceptinW [135]. Several studies reveal that high levels of
shed HER2 are associated with high-grade tumors, lymph
node metastasis, and higher mortality of breast cancer
patients [136–138]. Thus, the capability for simultan-
eously removing both soluble and exosome associated
oncoproteins using the ADAPT™ system could offer a
unique strategy for improving the therapeutic outcomes
for cancer patients.
In a therapeutic context, the fact that the ADAPT™ sys-
tem can access soluble factors in the circulation but not
those within the tumor or regional lymph nodes makes
this device strategy suitable for metastatic cancers. Indeed,
tumor-derived exosomes have been demonstrated to
transport molecular signals involved in angiogenesis and
stroma remodeling for tumor cell adhesion and growth
during priming of the pre-metastatic niche [139,140].
Moreover, since exosome production is determined by
tumor size and growth rate [16,17], the duration and fre-
quency of ADAPT™ therapy would require optimizing in
order to achieve a clinically beneficial level of exosome de-
pletion from the circulation. The device strategy could
also be tailored for different types/stages of cancer and
using devices incorporating different affinity agent(s). Cur-
rently, although a spectrum of biologic effects of cancer
exosomes have been identified in vitro and in experimen-
tal animals, the impact of diminishing exosomes thera-
peutically must still be studied in terms of the potential
efficacy in promoting immune recovery and hindering
tumor growth in a clinical setting.
Conclusions
Exosomes have emerged as being important vehicles for
intercellular communication and for modulating immune
responses, owing to their content of proteins and genetic
material that mirror their cells of origin. Whereas exosomes
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tory functions, there are many physiologic examples of exo-
somes exerting tolerogenic functions during dampening of
immune responses, oral tolerance and pregnancy. In cancer,
the tolerogenic activities of exosomes represent pathological
responses whereby tumor cells secrete vast amounts of im-
mune inhibitory exosomes that hinder anti-cancer immune
responses. Tumor-derived exosomes are involved in the
fundamental aspects of cancer pathogenesis including
growth, metastasis, angiogenesis, and immune suppression.
Therefore, to address the unmet need for a strategy to tar-
get tumor-secreted exosomes, one possible option involves
a therapeutic hemofiltration approach, the Aethlon
ADAPT™ system, which is designed to selectively capture
and remove target particles such as exosomes from the en-
tire circulatory system. This technology consists of hollow
fiber plasma filtration cartridges constructed with affinity
agents that are fitted for existing dialysis machines. The
ADAPT™ system has the potential to address a variety of
types and stages of cancer since it can incorporate diverse
affinity agents for capturing cancer-specific exosomes on
the basis of their display of surface proteins (using anti-
bodies) and/or glycoproteins (using lectin affinity agents).
The emerging evidence that tumor-secreted exosomes are
involved in mediating resistance to therapies provides an
impetus for exploration novel therapeutic options for
addressing the immune inhibitory and tumor growth-
promoting effects of cancer exosomes.
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